Evidence map›Paper›PMID 29976675›Full record

ArticleJournal of virology2018

Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.

Ara G Hovanessian, Calaiselvy Soundaramourty, Rima Benferhat, Roger Le Grand, Nathalie Dereuddre-Bosquet, Bernard Krust, Jérôme Estaquier

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ara G HovanessianCNRS FR3636, Université Paris Descartes, Paris, France arahovanessian@gmail.com estaquier@yahoo.fr.
Calaiselvy SoundaramourtyCNRS FR3636, Université Paris Descartes, Paris, France.
Rima BenferhatCNRS FR3636, Université Paris Descartes, Paris, France.
Roger Le GrandCEA, DRF/IMETI, IMVA-UMR1184, IDMIT infrastructure, Fontenay-aux-Roses, France.
Nathalie Dereuddre-BosquetCEA, DRF/IMETI, IMVA-UMR1184, IDMIT infrastructure, Fontenay-aux-Roses, France.
Bernard Krust *CNRS FR3636, Université Paris Descartes, Paris, France.
Jérôme Estaquier *CNRS FR3636, Université Paris Descartes, Paris, France arahovanessian@gmail.com estaquier@yahoo.fr.
Université Paris Cité · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRDélégation Paris 5 · FRInfectious Disease Models and Innovative Therapies · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously reported that the CBD1 peptide (SLEQIWNNMTWMQWDK), corresponding to the consensus caveolin-1 binding domain in human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp41, elicits peptide-specific antibodies. Here, we have investigated the cellular immune response and the protective efficacy against a simian/human immunodeficiency virus (SHIV

Indexed as

AIDS VaccinesAnimalsCaveolin 1CD4 Lymphocyte CountHIV-1HIV Envelope Protein gp41HIV InfectionsHumansImmunity, CellularImmunoglobulin GImmunologic MemoryMacaca fascicularisPeptidesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTh1 CellsAIDS VaccinesCaveolin 1CBD1 peptidegp41 protein, Human immunodeficiency virus 1HIV Envelope Protein gp41Immunoglobulin GPeptidesAIDSB cellCD4gp41HIVhuman immunodeficiency virusIgGimmunizationmacaquememory T cellssimian immunodeficiency virusSIVTh1TH1vaccine

Identifiers

PMID29976675
PMCPMC6146716
OpenAlexW2822351160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.